MX394876B - Formulaciones para el tratamiento del trastorno de estres post-traumatico. - Google Patents

Formulaciones para el tratamiento del trastorno de estres post-traumatico.

Info

Publication number
MX394876B
MX394876B MX2019014114A MX2019014114A MX394876B MX 394876 B MX394876 B MX 394876B MX 2019014114 A MX2019014114 A MX 2019014114A MX 2019014114 A MX2019014114 A MX 2019014114A MX 394876 B MX394876 B MX 394876B
Authority
MX
Mexico
Prior art keywords
post
stress disorder
traumatic stress
formulations
treatment
Prior art date
Application number
MX2019014114A
Other languages
English (en)
Other versions
MX2019014114A (es
Inventor
Daniel C Javitt
Original Assignee
Glytech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glytech Llc filed Critical Glytech Llc
Publication of MX2019014114A publication Critical patent/MX2019014114A/es
Publication of MX394876B publication Critical patent/MX394876B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente invención se describen compuestos para reducir los síntomas del trastorno por estrés postraumático. Los compuestos incluyen una combinación de un antagonista del receptor N-metil-D- aspartato (NMDA), y un agente antidepresivo.
MX2019014114A 2017-05-25 2018-05-24 Formulaciones para el tratamiento del trastorno de estres post-traumatico. MX394876B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762510801P 2017-05-25 2017-05-25
US201762518020P 2017-06-12 2017-06-12
PCT/IL2018/050567 WO2018216018A1 (en) 2017-05-25 2018-05-24 Formulations for treatment of post-traumatic stress disorder

Publications (2)

Publication Number Publication Date
MX2019014114A MX2019014114A (es) 2022-08-18
MX394876B true MX394876B (es) 2025-03-24

Family

ID=64396350

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019014114A MX394876B (es) 2017-05-25 2018-05-24 Formulaciones para el tratamiento del trastorno de estres post-traumatico.
MX2019014113A MX394875B (es) 2017-05-25 2018-05-24 Terapia combinada para trastornos neuropsiquiatricos sensibles al antagonista de nmdar.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019014113A MX394875B (es) 2017-05-25 2018-05-24 Terapia combinada para trastornos neuropsiquiatricos sensibles al antagonista de nmdar.

Country Status (13)

Country Link
US (4) US10881665B2 (es)
EP (2) EP3630102B1 (es)
JP (4) JP7312116B2 (es)
KR (2) KR102608479B1 (es)
CN (2) CN110996947A (es)
AU (2) AU2018274765A1 (es)
BR (2) BR112019024817A2 (es)
CA (2) CA3065003A1 (es)
IL (2) IL270916B2 (es)
MX (2) MX394876B (es)
RU (2) RU2019143573A (es)
WO (2) WO2018216020A1 (es)
ZA (2) ZA201908616B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019024817A2 (pt) * 2017-05-25 2020-08-18 Glytech Llc. formulações para tratamento de distúrbio de estresse pós-traumático
EP3505157B1 (en) 2017-12-29 2021-12-08 Celon Pharma S.A. Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
CN118453559A (zh) 2018-02-15 2024-08-09 国立大学法人千叶大学 炎症性疾病或骨病的预防或治疗剂及医药组合物
CN112533595A (zh) 2018-05-04 2021-03-19 感知神经科学公司 治疗物质滥用的方法
US20210386689A1 (en) * 2018-10-31 2021-12-16 Sunovion Pharmaceuticals Inc. Methods of treating central nervous system disorders
EP3952856A4 (en) * 2019-04-09 2023-01-11 Vistagen Therapeutics, Inc. GENETIC VARIATIONS ASSOCIATED WITH RESPONSE TO TREATMENT OF NEUROLOGICAL DISEASES
KR20220164470A (ko) * 2020-01-03 2022-12-13 유니버시티 오브 파도바 신경정신 장애 및 질병에 대한 질병-조절 치료제로서의 덱스트로메타돈
CN115677519A (zh) * 2021-07-22 2023-02-03 立科时代(武汉)生物科技有限公司 L-4-溴-犬尿氨酸及其在制备治疗抑郁症药物中的应用
CN113648320A (zh) * 2021-08-16 2021-11-16 中国人民解放军军事科学院军事医学研究院 赛洛西宾抗创伤后应激障碍的医药用途
WO2025004042A1 (en) * 2023-06-29 2025-01-02 The Sarah Herzog Memorial Hospital-Ezrath Nashim Nmdar antagonist for the treatment of inflammatory diseases in patients with depression comorbidity
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391922B1 (en) 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
PT1073432E (pt) * 1998-04-14 2007-10-22 Gen Hospital Corp Utilização da d-alanina ou da d-serina para o tratamento da esquizofrenia
US20050096396A1 (en) * 2002-03-28 2005-05-05 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
WO2005016319A2 (en) * 2003-08-06 2005-02-24 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
SI1587789T1 (sl) 2003-01-16 2009-02-28 Acadia Pharm Inc Selektivni inverzni agonisti serotoninskega 2A/2Creceptorja kot terapevtiki za nevrodegenerativne bolezni
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US20050209218A1 (en) 2004-02-13 2005-09-22 Meyerson Laurence R Methods and compositions for the treatment of psychiatric conditions
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
ES2412207T3 (es) 2004-09-27 2013-07-10 Acadia Pharmaceuticals Inc. Forma cristalina de hemitartrato de N-(4-fluorobencil)-N-(1-metilpiperidin-4-il)-N'-(4-(2-metilpropiloxi)fenilmetil)carbamida
TW200631584A (en) * 2004-11-15 2006-09-16 Akzo Nobel Nv A medicament related to mirtazapine for the treatment of hot flush
EP2099444A4 (en) 2006-12-14 2012-11-07 Nps Pharma Inc USE OF D-SERIN DERIVATIVES FOR THE TREATMENT OF ANTIBODIES
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
EP2670409B1 (en) 2011-01-31 2018-04-18 Serotech, LLC Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
AU2013251426A1 (en) 2012-04-27 2014-11-20 Indiana University Research And Technology Corporation Compositions and methods for treating PTSD and related diseases
SMT202000398T1 (it) * 2013-10-18 2020-09-10 Emalex Biosciences Inc Benzazepine fuse per il trattamento della balbuzie
WO2016049048A1 (en) 2014-09-22 2016-03-31 Rugen Holdings (Cayman) Limited Treatment of anxiety disorders and autism spectrum disorders
WO2016061320A2 (en) * 2014-10-15 2016-04-21 Rowan University Timber therapy for post-traumatic stress disorder
JP2018526345A (ja) 2015-08-04 2018-09-13 コンフルーエンス ファーマシューティカルズ，エルエルシー アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法
US20190054067A1 (en) * 2016-03-15 2019-02-21 University Of The Sciences Compositions and methods for treating compulsive-like behavior in a subject
BR112019024817A2 (pt) * 2017-05-25 2020-08-18 Glytech Llc. formulações para tratamento de distúrbio de estresse pós-traumático

Also Published As

Publication number Publication date
IL270885B1 (en) 2024-03-01
JP7537675B2 (ja) 2024-08-21
RU2019143573A3 (es) 2021-09-03
EP3630103A4 (en) 2021-04-14
JP2020520975A (ja) 2020-07-16
JP7312116B2 (ja) 2023-07-20
US20180338956A1 (en) 2018-11-29
MX2019014113A (es) 2022-08-18
MX394875B (es) 2025-03-24
US11969431B2 (en) 2024-04-30
CN110996947A (zh) 2020-04-10
AU2018274765A1 (en) 2020-01-23
BR112019024802A2 (pt) 2020-07-21
WO2018216020A1 (en) 2018-11-29
KR20200020726A (ko) 2020-02-26
JP7308761B2 (ja) 2023-07-14
RU2019143573A (ru) 2021-06-28
US20220143041A1 (en) 2022-05-12
KR102608479B1 (ko) 2023-12-01
EP3630103C0 (en) 2024-10-30
US10881665B2 (en) 2021-01-05
US20180338983A1 (en) 2018-11-29
IL270916A (en) 2020-01-30
IL270885B2 (en) 2024-07-01
MX2019014114A (es) 2022-08-18
RU2019143572A (ru) 2021-06-25
JP2023071900A (ja) 2023-05-23
EP3630102B1 (en) 2024-08-14
EP3630102A4 (en) 2021-04-14
JP2020520968A (ja) 2020-07-16
EP3630102A1 (en) 2020-04-08
BR112019024817A2 (pt) 2020-08-18
CA3065003A1 (en) 2018-11-29
ZA201908616B (en) 2021-09-29
EP3630103A1 (en) 2020-04-08
JP2023100904A (ja) 2023-07-19
AU2018274767A1 (en) 2020-01-30
EP3630103B1 (en) 2024-10-30
IL270916B1 (en) 2024-12-01
KR20200021477A (ko) 2020-02-28
ZA201908617B (en) 2022-01-26
CA3064846A1 (en) 2018-11-29
WO2018216018A1 (en) 2018-11-29
IL270916B2 (en) 2025-04-01
CN110996946A (zh) 2020-04-10
KR102654569B1 (ko) 2024-04-05
EP3630102C0 (en) 2024-08-14
JP7585369B2 (ja) 2024-11-18
IL270885A (en) 2020-01-30
US20210128579A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
MX2019014114A (es) Formulaciones para el tratamiento del trastorno de estres post-traumatico.
CY1121675T1 (el) Διαμορφωτες υποδοχεων nmdα σπeipο-λακταμης και χρησεις αυτων
MX2022015755A (es) Profarmacos de hormona paratiroidea (pth).
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2017006320A (es) Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
ZA201603342B (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
NZ737399A (en) Ccr2 modulators
MX2017001971A (es) Composiciones antimetanogenicas y sus usos.
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
CY1124490T1 (el) Μια διεργασια για την παρασκευη ενος σκευασματος ξηρης σκονης που περιλαμβανει ενα αντιχολινεργικο, ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο
ZA202507395B (en) Semaglutide in cardiovascular conditions
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
MX2021006941A (es) Anelosomas para suministrar modalidades terapéuticas intracelulares.
MX2016013431A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
CO2020005485A2 (es) Administración oral de análogos del péptido glp-1
MX2020005483A (es) Antagonistas de ildr2 y combinaciones de los mismos.
PH12019500326A1 (en) Combination of fxr agonists
GEP20186908B (en) P-substituted asymmetric ureas and medical uses thereof
MX2019003889A (es) Composiciones de combinacion que comprenden agonistas de fxr para tratar o prevenir una enfermedad o trastorno fibrotico o cirrotico.
PH12017502148A1 (en) Pharmaceutical compositions and use thereof
IL277358A (en) Omniphilic nanovesicles based on modified polysaccharides for the delivery of active substances
EA201990481A1 (ru) Тройная комбинация обратных агонистов рецептора гистамина-3, ингибиторов ацетилхолинэстеразы и антагониста рецептора nmda
NZ739679A (en) Cholecalciferol sulfate salts and their use for the treatment of vitamin d deficiency